LINC02568 therefore serves as a potential therapeutic target in ER+ breast cancer, and ASO targeting LINC02568 might provide a promising treatment option for ER+ breast cancer patients with primary and acquired endocrine therapy drug resistance. Here, LINC02568 is linked to breast carcinoma.